CymaBay Therapeutics, Inc.
CBAY
Kedudukan dalam Saham
#5775
CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical... CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.
Harga Saham
$32.48
Disegerakkan terakhir: 2024-03-25
Modal Pasaran
$2.24B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-0.01%
Negara
US
Perdagangan CymaBay Therapeutics, Inc. (CBAY)
Kategori
Healthcare
Sejarah harga saham bagi CymaBay Therapeutics, Inc. (CBAY)
Harga penutupan tertinggi: $32.38 pada 2024-03-01
Harga penutupan terendah: $11.69 pada 2018-01-01
Harga penutupan terendah: $11.69 pada 2018-01-01
Sejarah harga saham CymaBay Therapeutics, Inc. dari 2018 hingga 2026
Prestasi harga saham tahunan
| Tahun | Prestasi |
|---|---|
| 2024 | 49.45% |
| 2023 | 354.32% |
| 2022 | 40.76% |
| 2021 | -44.18% |
| 2019 | -15.64% |
| 2018 | 0.00% |
Harga saham bagi syarikat atau pesaing serupa
| Syarikat | Harga saham | Perubahan 1thn% | Negara |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $766.95 | 9.01% |
CH
|
